RCKT Stock Summary and Trading Ideas (Rocket Pharmaceuticals | NASDAQ:RCKT)

Rocket Pharmaceuticals Inc is a late-stage biopharmaceutical company. It is focused on the development of gene therapies for rare and devastating pediatric diseases. The pipeline products of the company include RP-A501 for Danaon Disease, RP-L102 for Fanconi Anemia, RP-L201 for Leukocyte Adhesion, RP-L301 for Pyruvate Kinase Deficiency, and RP-L401 for Infantile Malignant Osteopetrosis. It has one reportable segment related to R&D and commercial readiness of its gene therapies.

Rocket Pharmaceuticals trades on the NASDAQ stock market under the symbol RCKT.

As of June 26, 2026, RCKT stock price climbed to $3.25 with 6,258,404 million shares trading.

RCKT has a beta of 1.46, meaning it tends to be more sensitive to market movements. RCKT has a correlation of 0.07 to the broad based SPY ETF.

RCKT has a market cap of $354.82 million. This is considered a Small Cap stock.

In the last 3 years, RCKT traded as high as $32.53 and as low as $2.19.

The top ETF exchange traded funds that RCKT belongs to (by Net Assets): VTI, IWM, VXF, IBB, IWN.

RCKT has outperformed the market in the last year with a price return of +22.6% while the SPY ETF gained +21.3%. However, in the short term, RCKT had mixed performance relative to the market. It has underperformed in the last 3 months, returning -30.6% vs +11.3% return in SPY. But in the last 2 weeks, RCKT shares have fared better than the market returning +22.2% compared to SPY -0.9%.

RCKT support price is $3.11 and resistance is $3.37 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that RCKT shares will trade within this expected range on the day.